Cardiff Oncology, INC DEF 14A proxy statements

Cardiff Oncology, Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, and an increase in equity incentive plan shares.

Cardiff Oncology's upcoming annual meeting will address director elections, auditor ratification, an equity incentive plan amendment, and executive compensation.

Cardiff Oncology is holding its annual meeting of stockholders on June 26, 2025, to vote on key proposals including the election of directors, ratification of the accounting firm, an increase to the equity incentive plan, and executive compensation.

Cardiff Oncology is seeking stockholder approval for replacement stock option grants after rescinding previous grants made in reliance on a 2022 amendment to the 2021 Equity Incentive Plan.

Cardiff Oncology amended its by-laws to clarify voting standards and address a stockholder lawsuit alleging improper voting procedures.

Cardiff Oncology's upcoming annual meeting on June 20, 2024, will address the election of directors, ratification of auditors, an amendment to the equity incentive plan, and executive compensation.

Cardiff Oncology is holding its annual meeting to vote on key proposals including director elections, auditor ratification, an increase to the equity incentive plan, and executive compensation.